Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can Neoadjuvant Chemoradiotherapy be Omitted in cT2N+ and cT3 Mid-rectal Cancer: A Prospective, Observational Cohort Study

NCT06823297 is registered in ClinicalTrials.gov with Turkish Society of Colon and Rectal Surgery as lead sponsor.

NCT NCT06823297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06823297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can Neoadjuvant Chemoradiotherapy be Omitted in cT2N+ and cT3 Mid-rectal Cancer: A Prospective, Observational Cohort Study
Lead sponsor
Turkish Society of Colon and Rectal Surgery
Phase
Observational
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
August 1, 2035
Enrollment
436 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

mid-rectal cancer, rectal cancer stage ii, rectal cancer stage iii